var data={"title":"Warfarin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Warfarin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7164?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=warfarin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Warfarin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=warfarin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Warfarin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708848\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bleeding risk:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin can cause major or fatal bleeding. Perform regular monitoring of international normalized ratio (INR) on all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin therapy. Instruct patients about prevention measures to minimize the risk of bleeding and to report immediately to their health care provider signs and symptoms of bleeding.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234876\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Coumadin;</li>\n      <li>Jantoven</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234877\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Warfarin;</li>\n      <li>Coumadin;</li>\n      <li>Mylan-Warfarin;</li>\n      <li>Novo-Warfarin;</li>\n      <li>Taro-Warfarin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234916\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Vitamin K Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234880\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Coumadin injection has been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Labeling identifies genetic factors which may increase patient sensitivity to warfarin. Specifically, genetic variations in the proteins CYP2C9 and VKORC1, responsible for warfarin's primary metabolism and pharmacodynamic activity, respectively, have been identified as predisposing factors associated with decreased dose requirement and increased bleeding risk. Genotyping tests are available, and may provide guidance on initiation of anticoagulant therapy. The American College of Chest Physicians recommends against the use of routine pharmacogenomic testing to guide dosing (Guyatt 2012). For management of elevated INRs as a result of warfarin therapy, see Additional Information/Pharmacotherapy Pearls for guidance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Thromboembolic complications (prophylaxis/treatment) or myocardial infarction (risk reduction):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV (administer as a slow bolus injection):</i> 2 to 5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial dosing must be individualized. Consider the patient (hepatic function, cardiac function, age, nutritional status, concurrent therapy, risk of bleeding) in addition to prior dose response (if available) and the clinical situation. Start 2 to 5 mg once daily <b>or</b> for healthy individuals, 10 mg once daily for 2 days; lower doses (eg, 5 mg once daily) recommended for patients with confirmed HIT once platelet recovery has occurred (Guyatt 2012). In patients with acute venous thromboembolism, initiation may begin on the first or second day of low molecular weight heparin or unfractionated heparin therapy (Guyatt 2012). Adjust dose according to INR results; usual maintenance dose ranges from 2 to 10 mg daily (individual patients may require loading and maintenance doses outside these general guidelines).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note</b>: Lower starting doses may be required for patients with hepatic impairment, poor nutrition, CHF, elderly, high risk of bleeding, or patients who are debilitated, or those with reduced function genomic variants of the catabolic enzymes CYP2C9 (*2 or *3 alleles) or VKORC1 (-1639 polymorphism); see table. Higher initial doses may be reasonable in selected patients (ie, receiving enzyme-inducing agents and with low risk of bleeding). Overlapping a parenteral anticoagulant and warfarin therapy by at least 5 days is necessary in treatment of DVT/PE even if the INR is therapeutic earlier. Although an elevation in INR (due to factor VII depletion) may be seen early (within the first 24 to 48 hours) in warfarin therapy, it does not represent adequate anticoagulation. Factors II and X must also be depleted which takes considerably longer (ACCP [Guyatt 2012]).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Range<sup>1</sup> of Expected Therapeutic Maintenance Dose Based on CYP2C9<sup>2</sup> and VKORC1<sup>3</sup> Genotypes</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">VKORC1</p></th>\n          <th colspan=\"6\" align=\"center\">\n            <p style=\"text-indent:0em;\">CYP2C9</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <b>Note:</b> Must also take into account other patient related factors when determining initial dose (eg, age, body weight, concomitant medications, comorbidities). The American College of Chest Physicians recommends against the use of routine pharmacogenomic testing to guide dosing (Guyatt, 2012).</p></td></tr>\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>1</sup>Ranges derived from multiple published clinical studies.</p></td></tr>\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>2</sup>Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 alleles may take up to 4 weeks to achieve maximum INR with a given dose regimen.</p></td></tr>\n        <tr>\n          <td colspan=\"7\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>3</sup>VKORC1 -1639G&gt;A (rs 9923231) variant is used in this table; other VKORC1 variants may also be important determinants of dose.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">*1/*1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">*1/*2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">*1/*3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">*2/*2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">*2/*3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">*3/*3</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>GG</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-7 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-7 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5-2 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>AG</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-7 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5-2 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5-2 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>AA</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5-2 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5-2 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5-2 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5-2 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Duration of therapy:</b></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">\n        <b>Warfarin Duration of Therapy by Indication</b></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Indication</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Duration of therapy</p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>1</sup>Extended therapy is defined as after first 3 months of treatment and with no scheduled stop date. All patients receiving extended or indefinite therapy should be reassessed at periodic intervals for continuing use of therapy.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;text-align:left;\">LV = left ventricular; DVT = deep vein thrombosis, AF = atrial flutter, VTE = venous thromboembolism, PE = pulmonary embolism, LMWH = low molecular weight heparin, MI = myocardial infarction</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">AF (including AF and mitral stenosis, AF and stable coronary artery disease) (January 2014)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Indefinite<sup>1</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Bioprosthetic valves in the mitral position (Whitlock 2012)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 months after valve insertion</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Mechanical prosthetic cardiac valves (Whitlock 2012)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Indefinite<sup>1</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Anterior MI with LV thrombus or at high risk for LV thrombus (Vandvik 2012)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 months after MI</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <i>VTE (</i>Kearon 2012; Kearon 2016)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">First episode, provoked or unprovoked DVT of the leg or PE (<i>without</i> cancer)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 months minimum or extended therapy<sup>1</sup> may be considered in patients who do not have a high risk of bleeding</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Unprovoked second DVT of the leg or PE</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Extended therapy<sup>1 </sup>is recommended in patients who do not have a high risk of bleeding</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">In patients with DVT of the leg or PE and <i>with</i> cancer</p>\n            <p style=\"text-indent:0em;\">\n              <b>Note:</b> LMWH is preferred over oral anticoagulation for treatment of patients <i>with</i> cancer</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Extended therapy<sup>1</sup> is recommended, although high bleeding risk confers a lower grade of recommendation.</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234898\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=warfarin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Warfarin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Coumadin injection has been discontinued in the US for more than 1 year.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Labeling identifies genetic factors which may increase patient sensitivity to warfarin. Specifically, genetic variations in the proteins CYP2C9 and VKORC1, responsible for warfarin's primary metabolism and pharmacodynamic activity, respectively, have been identified as predisposing factors associated with decreased dose requirement and increased bleeding risk. Genotyping tests are available, and may provide guidance on initiation of anticoagulant therapy. The American College of Chest Physicians recommends against the use of routine pharmacogenomic testing to guide dosing (Guyatt 2012). For management of elevated INRs as a result of warfarin therapy, see Additional Information/Pharmacotherapy Pearls for guidance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prevention/treatment of thrombosis:</b> Infants and Children (off-label use): Oral: Initial loading dose (if baseline INR is 1-1.3): 0.2 mg/kg (maximum: 10 mg/dose); adjust dose based on INR (reported ranges to maintain INR of 2 to 3: 0.09 to 0.33 mg/kg/day). Infants &lt;12 months of age may require doses at or near the high end of this range; consistent anticoagulation may be difficult to maintain in children &lt;5 years of age (Monagle 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234881\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Thromboembolic complications (prophylaxis/treatment) or myocardial infarction (risk reduction):</b> Oral: Initial dose &le;5 mg. Usual maintenance dose: 2 to 5 mg/day. Patients &gt;60 years of age tend to require lower dosages to produce a therapeutic level of anticoagulation (due to changes in the pattern of warfarin metabolism).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401678\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment necessary. However, patients with renal impairment have an increased risk for bleeding diathesis; monitor INR closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234882\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, the response to oral anticoagulants may be markedly enhanced in obstructive jaundice, hepatitis, and cirrhosis. INR should be closely monitored.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234849\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 5 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 1 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 2 mg [scored; contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 2.5 mg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 3 mg [scored; contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 4 mg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 5 mg [scored; contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 6 mg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 7.5 mg [scored; contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin: 10 mg [scored; dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 1 mg [scored; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 2 mg [scored; contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 2.5 mg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 3 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 4 mg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 5 mg [scored; contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 6 mg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 7.5 mg [scored; contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven: 10 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234833\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28843154\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Coumadin injection has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874933\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s017lbl.pdf#page=31&amp;token=rDUguuTslPRpKDxOJx3c/r8jpsWXElVervv6K6zPDgEtXs/dGflC/sqF9bcqKbQEZqN9jQCORCPQemPqv21V3FOaUuobOvY4hMWjuCavFi7Ef2ozGv1OIgCUqN8H9dsr&amp;TOPIC_ID=689\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s017lbl.pdf#page=31</a> (Coumadin), must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234853\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer as a slow bolus injection over 1 to 2 minutes; avoid all IM injections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104604\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234852\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thromboembolic complications:</b> Prophylaxis and treatment of thromboembolic disorders (eg, venous, pulmonary) and embolic complications arising from atrial fibrillation or cardiac valve replacement:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonvalvular AF or atrial flutter: The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines for the management of AF recommend oral anticoagulation for patients with nonvalvular AF or atrial flutter with prior stroke, TIA, or a CHA<sub>2</sub>DS<sub>2</sub>-VASc score &ge;2. In patients with AF or atrial flutter of &ge;48 hours duration or when the duration is unknown, anticoagulation with warfarin is recommended for at least 3 weeks prior to and 4 weeks after cardioversion regardless of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and method used to restore sinus rhythm (AHA/ACC [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Valvular AF: The 2014 American Heart Association/American Stroke Association (AHA/ASA) guidelines for the primary prevention of stroke recommend chronic oral anticoagulation with warfarin for patients with valvular atrial fibrillation at high risk for stroke, defined as a CHA2DS2-VASc score of &ge;2, and acceptably low risk for hemorrhagic complications (AHA/ASA [Meschia 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mechanical prosthetic cardiac valves: The 2014 American Heart Association/American Stroke Association (AHA/ASA) guidelines for the primary prevention of stroke recommend warfarin and low-dose aspirin in the patients who have received an aortic mechanical prosthetic valve (with or without risk factors) or any mitral mechanical prosthetic valve. Target INRs vary depending on valve position and/or risk factors (AHA/ASA [Meschia 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Venous thromboembolism (VTE): The American College of Chest Physicians (ACCP) recommends dabigatran, rivaroxaban, apixaban, or edoxaban over warfarin for the initial and long-term treatment of VTE in patients <i>without </i>cancer. For the treatment of VTE in patients <i>with</i> cancer, ACCP recommends LMWH over oral anticoagulants (warfarin or dabigatran, rivaroxaban, apixaban, or edoxaban) for initial and long-term treatment (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myocardial infarction:</b> Adjunct to reduce risk of systemic embolism (eg, recurrent MI, stroke) after myocardial infarction:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">According to the American College of Cardiology/American Heart Association (ACCF/AHA) guidelines for the management of patients with ST-elevation myocardial infarction (STEMI), warfarin should be administered to patients with STEMI and AF and a CHADS<sub>2</sub> score of 2 or more, mechanical valve, venous thromboembolism, or hypercoagulable disorder. Use is reasonable in patients with STEMI and asymptomatic LV mural thrombi and may be considered in patients with STEMI and anterior apical akinesis or dyskinesis (O'Gara 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Warfarin has no direct effect on an established thrombus and does not reverse ischemic tissue damage. The goal of anticoagulant therapy is to prevent further extension of an already formed thrombus and to prevent secondary thromboembolic complications that may result in serious and potentially fatal sequelae.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744940\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Recurrent stroke/Transient ischemic attacks (secondary prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234925\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coumadin may be confused with Cardura, Compazine, Kemadrin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jantoven may be confused with Janumet, Januvia </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">National Patient Safety Goals:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Joint Commission on Accreditation of Healthcare Organizations requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234840\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Bleeding is the major adverse effect of warfarin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Major hemorrhage (&le;5%; INR 2.5 to 4.0 generally associated with more bleeding)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Purple-toe syndrome, systemic cholesterol micro-embolism, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, bullous rash, dermatitis, pruritus, skin necrosis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, bloating, diarrhea, dysgeusia, flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Minor hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure (in patients with altered glomerular integrity or with a history of kidney disease)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Tracheobronchial calcification</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Gangrene of skin or other tissue, skin necrosis, vascular calcification (calcium uremic arteriolopathy and calciphylaxis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234856\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to warfarin or any component of the formulation; hemorrhagic tendencies (eg, active GI ulceration, patients bleeding from the GI, respiratory, or GU tract; cerebral aneurysm; CNS hemorrhage; dissecting aortic aneurysm; spinal puncture and other diagnostic or therapeutic procedures with potential for significant bleeding); recent or potential surgery of the eye or CNS; major regional lumbar block anesthesia or traumatic surgery resulting in large, open surfaces; blood dyscrasias; malignant hypertension; pericarditis or pericardial effusion; bacterial endocarditis; unsupervised patients with conditions associated with a high potential for noncompliance; eclampsia/preeclampsia, threatened abortion, pregnancy (except in women with mechanical heart valves at high risk for thromboembolism) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234837\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute kidney injury: Acute kidney injury, possibly as a result of episodes of excessive anticoagulation and hematuria, may occur in patients with a history of kidney disease or in patients with altered glomerular integrity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity: May cause hypersensitivity reactions, including anaphylaxis; use with caution in patients with anaphylactic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: <b>[US Boxed Warning]: May cause major or fatal bleeding. Perform regular INR monitoring in all treated patients. INR levels achieved with warfarin therapy may be affected by concomitant medication, dietary modifications and/or other factors (eg, smoking).</b> Risk factors for bleeding include high intensity anticoagulation (INR &gt;4), age (&ge;65 years), variable INRs, history of GI bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, severe diabetes, malignancy, trauma, renal insufficiency, polycythemia vera, vasculitis, open wound, history of PUD,  indwelling catheters, menstruating and postpartum women, drug-drug interactions, long duration of therapy, or known genetic deficiency in CYP2C9 activity. <b>Patient must be instructed to report bleeding, accidents, or falls as well as any new or discontinued medications, herbal or alternative products used, or significant changes in smoking or dietary habits.</b> Unrecognized bleeding sites (eg, colon cancer) may be uncovered by anticoagulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Calciphylaxis: Fatal and serious calciphylaxis (calcium uremic arteriolopathy) has been reported in patients with and without end-stage renal disease. If calciphylaxis is diagnosed, discontinue therapy and treat calciphylaxis as appropriate. Consider alternative anticoagulation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin necrosis/gangrene: Necrosis or gangrene of the skin and other tissue can occur (rarely, &lt;0.1%) due to paradoxical local thrombosis; onset is usually within the first few days of therapy and is frequently localized to the limbs, breast, or penis. The risk of this effect is increased in patients with protein C or S deficiency. Consider alternative therapies if anticoagulation is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atheroemboli/cholesterol microemboli: Warfarin therapy may release atheromatous plaque emboli; symptoms depend on site of embolization, most commonly kidneys, pancreas, liver, and spleen. In some cases may lead to necrosis or death. &ldquo;Purple toe&rdquo; syndrome, due to cholesterol microembolization, has been rarely described with coumarin-type anticoagulants. Typically, this occurs after several weeks of therapy, and may present as a dark, purplish, mottled discoloration of the plantar and lateral surfaces. Other manifestations of cholesterol microembolization may include rash; livedo reticularis; gangrene; abrupt and intense pain in lower extremities; abdominal, flank, or back pain; hematuria, renal insufficiency; hypertension; cerebral ischemia; spinal cord infarction; or other symptoms of vascular compromise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dietary insufficiency: Use with caution in patients with prolonged dietary insufficiencies (vitamin K deficiency).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heparin-induced thrombocytopenia: Use with caution in patients with heparin-induced thrombocytopenia and DVT; limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was stopped. Warfarin monotherapy is contraindicated in the initial treatment of active HIT; warfarin initially inhibits the synthesis of protein C, potentially accelerating the underlying active thrombotic process.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Reduced liver function, regardless of etiology, may impair synthesis of coagulation factors leading to increased warfarin sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Use with caution in patients with acute infection or active TB or any disruption of normal GI flora; antibiotics and fever may alter response to warfarin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Patients with renal impairment are at increased risk for bleeding diathesis; frequent INR monitoring is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Use with caution in patients with thyroid disease; warfarin responsiveness may increase (Ageno 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: The elderly may be more sensitive to anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients with genomic variants in CYP2C9 and/or VKORC1: Presence of the CYP2C9*2 or *3 allele and/or polymorphism of the vitamin K oxidoreductase (VKORC1) gene may increase the risk of bleeding. The *2 allele is reported to occur with a frequency of 4% to 11% in African-Americans and Caucasians, respectively, while the *3 allele frequencies are 2% to 7% respectively. Other variant 2C9 alleles (eg, *5, *6, *9, and *11) are also associated with reduced metabolic activity and thus may increase risk of bleeding, but are much less common. Lower doses may be required in these patients; genetic testing may help determine appropriate dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Surgical patients: When temporary interruption is necessary before surgery, discontinue for approximately 5 days before surgery; when there is adequate hemostasis, may reinstitute warfarin therapy ~12 to 24 hours after surgery (evening of or next morning). Decision to safely continue warfarin therapy through the procedure and whether or not bridging of anticoagulation is necessary is dependent upon risk of perioperative bleeding and risk of thromboembolism, respectively. If risk of thromboembolism is elevated, consider bridging warfarin therapy with an alternative anticoagulant (eg, unfractionated heparin, LMWH) (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient selection: Use care in the selection of patients appropriate for this treatment; ensure patient cooperation especially from the alcoholic, illicit drug user, demented, or psychotic patient; ability to comply with routine laboratory monitoring is essential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234911\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234842\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10050&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May decrease the serum concentration of Vitamin K Antagonists. More specifically, this effect has been described in heavy drinking alcoholic patients (over 250 g alcohol daily for over 3 months).  The role of alcohol itself is unclear.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. Management: Monitor patients extra closely for evidence of increased anticoagulant effects if amiodarone is started.  Consider empiric reduction of 30% to 50% in warfarin dose, though no specific guidelines on dose adjustment have been published.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral NS5B RNA Polymerase Inhibitors: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzbromarone: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bicalutamide: May increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bifonazole: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May increase the metabolism of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Vitamin K Antagonists. Management: Monitor for decreased INR and effects of vitamin K antagonists if carbamazepine is initiated/dose increased, or increased INR and effects if carbamazepine is discontinued/dose decreased. Warfarin dose adjustments will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Hydrate: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol (Systemic) may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chondroitin Sulfate: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: May enhance the anticoagulant effect of Warfarin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coenzyme Q-10: May diminish the anticoagulant effect of Vitamin K Antagonists. Coenzyme Q-10 may enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cranberry: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inducers (Moderate): May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desvenlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dicloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Warfarin. Specifically, dronabinol may displace warfarin from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Econazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Vitamin K Antagonists. Efavirenz may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of Warfarin. More specifically, enzalutamide may decrease concentrations of the S-warfarin enantiomer. Management: Avoid concurrent use of warfarin and enzalutamide whenever possible.  If the combination must be used, conduct additional INR monitoring as serum concentrations may be decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Ophthalmic): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eslicarbazepine: May decrease the serum concentration of Warfarin. Specifically, S-warfarin serum concentrations may be decreased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethacrynic Acid: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethotoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin. Management: Anticoagulant dose adjustment will likely be necessary when ethotoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exenatide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fat Emulsion (Fish Oil and Plant Based): May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: May enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenugreek: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Seek alternatives to fenugreek in patients receiving vitamin K antagonists. Monitor patients receiving these combinations closely for increases in INR and systemic effects of the vitamin K antagonist (particularly easy bruising and bleeding).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Flucloxacillin may decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Topical): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Vitamin K antagonist dose adjustments may be required when used with systemic fusidic acid.  Patients using this combination should be monitored extra closely for evidence of bleeding and to determine appropriate dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemcitabine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May enhance the adverse/toxic effect of Vitamin K Antagonists. Management: Consider avoiding the use of this combination of agents. Monitor for signs and symptoms of bleeding if vitamin K antagonists and Ginkgo biloba are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginseng (American): May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glutethimide: May increase the metabolism of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Green Tea: May enhance the adverse/toxic effect of Warfarin. Particularly, the risk of bleeding may be increased due to possible antiplatelet effects of green tea. Green Tea may diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): May enhance the anticoagulant effect of Vitamin K Antagonists.<b> Exceptions: </b>AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivermectin (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lansoprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the anticoagulant effect of Vitamin K Antagonists. Leflunomide may diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevOCARNitine: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomilnacipran: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Vitamin K Antagonists.<b> Exceptions: </b>Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menadiol Diphosphate: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Menatetrenone: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May decrease the serum concentration of Warfarin. Metreleptin may increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents.  If concomitant therapy cannot be avoided, consider reducing the dose of the vitamin K antagonist and monitor for increased INR/bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miconazole (Oral): May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miconazole (Topical): May increase the serum concentration of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Milnacipran: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the anticoagulant effect of Vitamin K Antagonists. Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Management: Consider choosing an alternative antibiotic. Monitor for decreased therapeutic effects and need for dose adjustments of oral anticoagulants if nafcillin is initiated/dose increased, or increased effects if nafcillin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: May decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neomycin: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Vitamin K Antagonists. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oritavancin: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May enhance the anticoagulant effect of Vitamin K Antagonists.<b> Exceptions: </b>Dicloxacillin; Nafcillin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phytonadione: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products. Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proguanil: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with higher doses (equivalent to acetaminophen doses exceeding 1.3 to 2 g/day) for multiple consecutive days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RaNITIdine: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: Warfarin may enhance the adverse/toxic effect of Regorafenib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Revaprazan: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May increase the metabolism of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RomiDEPsin: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roxithromycin: May enhance the anticholinergic effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Vitamin K Antagonists.<b> Exceptions: </b>Salsalate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates (Topical): May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: May enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin. Management: Warfarin dose adjustment will likely be necessary.  Increase frequency of INR monitoring during sorafenib therapy (particularly when starting or stopping therapy), and increase monitoring for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May increase the metabolism of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Streptokinase: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May decrease the metabolism of Vitamin K Antagonists. Sulfinpyrazone may decrease the protein binding of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: May increase the serum concentration of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: May increase the serum concentration of Vitamin K Antagonists. Management: Monitor INR and signs/symptoms of bleeding closely when starting or stopping this combination.  Anticoagulant dose adjustment will likely be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May decrease the serum concentration of Warfarin. Telaprevir may increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tigecycline: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolterodine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Torsemide: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tranilast (Systemic): May enhance the adverse/toxic effect of Warfarin. Tranilast (Systemic) may diminish the therapeutic effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraZODone: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorinostat: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zafirlukast: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zileuton: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234872\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Acute ethanol ingestion (binge drinking) decreases the metabolism of oral anticoagulants and increases PT/INR. Chronic daily ethanol use increases the metabolism of oral anticoagulants and decreases PT/INR. Management: Avoid ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: The anticoagulant effects of warfarin may be decreased if taken with foods rich in vitamin K. Vitamin E may increase warfarin effect. Cranberry juice may increase warfarin effect. Management: Maintain a consistent diet; consult prescriber before making changes in diet. Take warfarin at the same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234859\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Warfarin crosses the placenta; concentrations in the fetal plasma are similar to maternal values. Teratogenic effects have been reported following first trimester exposure and may include coumarin embryopathy (nasal hypoplasia and/or stippled epiphyses; limb hypoplasia may also be present). Adverse CNS events to the fetus have also been observed following exposure during any trimester and may include CNS abnormalities (including ventral midline dysplasia, dorsal midline dysplasia). Spontaneous abortion, fetal hemorrhage, and fetal death may also occur. Use is contraindicated during pregnancy (or in women of reproductive potential) except in women with mechanical heart valves who are at high risk for thromboembolism; use is also contraindicated in women with threatened abortion, eclampsia, or preeclampsia. Frequent pregnancy tests are recommended for women who are planning to become pregnant and adjusted-dose heparin or low molecular weight heparin (LMWH) should be substituted as soon as pregnancy is confirmed or adjusted-dose heparin or LMWH should be used instead of warfarin prior to conception.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In pregnant women with high-risk mechanical heart valves, the benefits of warfarin therapy should be discussed with the risks of available treatments (ACCP [Bates 2012]; AHA/ACC [Nishimura 2014]); when possible avoid warfarin use during the first trimester (ACCP [Bates 2012]) and close to delivery (ACCP [Bates 2012]; AHA/ACC [Nishimura 2014]). Use of warfarin during the first trimester may be considered if the therapeutic INR can be achieved with a dose &le;5 mg/day (AHA/ACC [Nishimura 2014]). Adjusted-dose LMWH or adjusted-dose heparin may be used throughout pregnancy or until week 13 of gestation when therapy can be changed to warfarin. LMWH or heparin should be resumed close to delivery. In women who are at a very high risk for thromboembolism (older generation mechanical prosthesis in mitral position or history of thromboembolism), warfarin can be used throughout pregnancy and replaced with LMWH or heparin near term; the use of low-dose aspirin is also recommended (ACCP [Bates 2012] AHA/ACC [Nishimura 2014]). Women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. If anti-Xa monitoring cannot be done, do not use LMWH therapy in pregnant patients with a mechanical prosthetic valve (AHA/ACC [Nishimura 2014]). When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (ACCP [Bates 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234860\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Based on available data, warfarin is not present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Breastfeeding women may be treated with warfarin. According to the American College of Chest Physicians (ACCP), warfarin may be used in lactating women who wish to breastfeed their infants (ACCP [Bates 2012]). The manufacturer recommends monitoring of breastfeeding infants for bruising or bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234861\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Foods high in vitamin K (eg, leafy green vegetables) inhibit anticoagulant effect. The list of usual foods with high vitamin K content is well known, however, some unique ones include green tea (<i>Camellia sinensis</i>), chewing tobacco, a variety of oils (canola, corn, olive, peanut, safflower, sesame seed, soybean, and sunflower) (Booth, 1999; Kuykendall, 2004; Nutescu, 2011). Snack foods containing Olestra have 80 mcg of vitamin K added to each ounce (Harrell, 1999). Some natural products may contain hidden sources of vitamin K (Nutescu, 2006). Avoid drastic changes in diet (eg, intake of large amounts of alfalfa, asparagus, broccoli, Brussels sprouts, cabbage, cauliflower, green teas, kale, lettuce, spinach, turnip greens, watercress) which decrease efficacy of warfarin. A balanced diet with a consistent intake of vitamin K is essential. The recommended dietary allowance for vitamin K in adults is 75 to 120 mcg/day (USDA Dietary Reference Intake).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234847\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Prothrombin time, hematocrit; INR (frequency varies depending on INR stability); may consider genotyping of CYP2C9 and VKORC1 prior to initiation of therapy, if available </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234850\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">INR = patient prothrombin time/mean normal prothrombin time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ISI = international sensitivity index</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">INR should be increased by 2 to 3.5 times depending upon indication. An INR &gt;4 does not generally add additional therapeutic benefit and is associated with increased risk of bleeding. <b>Note:</b> To prevent gastrointestinal bleeding events in patients receiving the combination of warfarin, aspirin, and clopidogrel, an INR of 2 to 2.5 is recommended unless condition requires a higher INR target (eg, certain mechanical heart valves) (Bhatt 2008).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Adult Target INR Ranges Based Upon Indication</caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Indication</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Targeted INR</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Targeted INR Range</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <b>Note:</b> Unless otherwise noted, all recommendations derived from &ldquo;Antithrombotic Therapy for VTE Disease&rdquo;, (Kearon 2012; Kearon 2016).</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>1</sup>If coronary stent placed, triple therapy (warfarin, low-dose aspirin, and clopidogrel) is recommended for 1 month (bare-metal stent) or 3-6 months (drug-eluting stent) followed by discontinuation of warfarin and use of dual antiplatelet therapy (eg, aspirin and clopidogrel) for up to 12 months.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>2</sup>If coronary stent <b>not </b>placed, maintain anticoagulation (in combination with low-dose aspirin) for 3 months followed by discontinuation of warfarin and use of dual antiplatelet therapy (eg, aspirin and clopidogrel) for up to 12 months.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>3</sup>The ACCF/AHA guidelines for the management of STEMI, suggest that a lower INR range of 2-2.5 might be considered in patients with STEMI receiving dual antiplatelet therapy (O&rsquo;Gara 2013).</p></td></tr>\n        <tr>\n          <td colspan=\"3\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>4</sup>Recommended for those patients with nonvalvular AF or atrial flutter with prior stroke, TIA, or a CHA<sub>2</sub>DS<sub>2</sub>-VASc score &ge;2 (AHA/ACC/HRS [January, 2014]).</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>5</sup>Recommendation from Stein, 2001.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>6</sup>If at low risk of bleeding, combine with aspirin 81 mg/day.</p></td></tr>\n        <tr>\n          <td colspan=\"3\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>7</sup>The AHA/ASA recommends use in patients with bileaflet mechanical or current-generation, single-tilting-disk prostheses (AHA/ASA [Meschia 2014]).</p></td></tr>\n        <tr>\n          <td colspan=\"3\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>8</sup>The On-X prosthetic aortic valve requires an initial INR of 2 to 3 for 3 months after valve insertion followed by an INR of 1.5 to 2 indefinitely. Unless contraindicated, continuous use of concurrent aspirin 75 to 100 mg daily is also recommended.</p></td></tr>\n        <tr>\n          <td colspan=\"3\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>9</sup>Risk factors defined by the AHA/ASA include atrial fibrillation, previous thromboembolism, left ventricular dysfunction, and hypercoagulable condition (AHA/ASA [Meschia 2014]).</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>10</sup>Maintain anticoagulation for 3 months after valve insertion then switch to aspirin 81 mg/day if no other indications for warfarin exist or clinically reassess need for warfarin in patients with prior history of systemic embolism.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>11</sup>Recommendation from the ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension (McLaughlin 2009)</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>12</sup>Continue for at least 10 to 14 days; up to 35 days after surgery is suggested.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>13</sup>Instead of adjusted dose warfarin, the use of dabigatran has been suggested. In either case, oral anticoagulation should be initiated within 1 to 2 weeks after stroke onset or earlier in patients at low bleeding risk; bridging with aspirin may be required.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Cardiac</b></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Anterior myocardial infarction with LV thrombus or high risk for LV thrombus (EF&lt;40%, anteroapical wall motion abnormality)<sup>1,2,3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Atrial fibrillation (nonvalvular)<sup>4</sup> or atrial flutter</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">LV systolic dysfunction (without established CAD) (eg, Takotsubo cardiomyopathy) with an LV thrombus</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Valvular</b></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Carbomedics or St. Jude Medical bileaflet or Medtronic Hall tilting disk mechanical aortic valve in normal sinus rhythm and normal LA size<sup>5</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Bileaflet or tilting disk mechanical mitral valve<sup>5</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5-3.5</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Caged ball or caged disk mechanical valve<sup>5</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5-3.5</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Mechanical aortic valve<sup>6,7,8</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Mechanical aortic valve (with risk factors<sup>6,9</sup>), mechanical mitral valve<sup>6</sup>, <b>or</b> mechanical valves in both the aortic and mitral positions<sup>6</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5-3.5</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Bioprosthetic mitral valve<sup>10</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Rheumatic mitral valve disease (particularly mitral stenosis) and normal sinus rhythm (LA diameter &gt;5.5 cm), AF, previous systemic embolism, or LA thrombus</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Thromboembolism Treatment </b></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Venous thromboembolism</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Thromboprophylaxis</b></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Idiopathic pulmonary artery hypertension (IPAH)<sup>11</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5-2.5</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Antiphospholipid syndrome (no other risk factors)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Antiphospholipid syndrome and recurrent thromboembolism</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Total hip or knee replacement or hip fracture surgery<sup>12</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Other Indications </b></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Ischemic stroke due to AF<sup>13</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Cryptogenic stroke (recurrent) and either patent foramen ovale (PFO) or atrial septal aneurysm</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Warfarin levels are not used for monitoring degree of anticoagulation. They may be useful if a patient with unexplained coagulopathy is using the drug surreptitiously or if it is unclear whether clinical resistance is due to true drug resistance or lack of drug intake.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal prothrombin time (PT): 10.9 to 12.9 seconds. Healthy premature newborns have prolonged coagulation test screening results (eg, PT, aPTT, TT) which return to normal adult values at approximately 6 months of age. Healthy prematures, however, do not develop spontaneous hemorrhage or thrombotic complications because of a balance between procoagulants and inhibitors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234836\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic synthesis of coagulation factors II (half-life 42 to 72 hours), VII (half-life 4 to 6 hours), IX, and X (half-life 27 to 48 hours), as well as proteins C and S, requires the presence of vitamin K. These clotting factors are biologically activated by the addition of carboxyl groups to key glutamic acid residues within the proteins&rsquo; structure. In the process, &ldquo;active&rdquo; vitamin K is oxidatively converted to an &ldquo;inactive&rdquo; form, which is then subsequently reactivated by vitamin K epoxide reductase complex 1 (VKORC1). Warfarin competitively inhibits the subunit 1 of the multi-unit VKOR complex, thus depleting functional vitamin K reserves and hence reduces synthesis of active clotting factors. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234855\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Anticoagulation: Oral: 24-72 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Full therapeutic effect: 5-7 days; INR may increase in 36-72 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 2-5 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid, complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 0.14 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, primarily via CYP2C9; minor pathways include CYP2C8, 2C18, 2C19, 1A2, and 3A4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Genomic variants:</i> Approximately 37% reduced clearance of S-warfarin in patients heterozygous for 2C9 (*1/*2 or *1/*3), and ~70% reduced in patients homozygous for reduced function alleles (*2/*2, *2/*3, or *3/*3)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 20-60 hours; Mean: 40 hours; highly variable among individuals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (92%, primarily as metabolites; minimal as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234858\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Coumadin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $247.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $258.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $266.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $267.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $268.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $277.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (100): $357.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $370.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $383.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Jantoven Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $61.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $64.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $66.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $66.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $66.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $68.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (100): $88.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $92.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $94.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Warfarin Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $58.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $63.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $62.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (100): $64.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $65.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $66.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (100): $92.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (100): $94.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $98.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234862\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldocumar (ES);</li>\n      <li>Azwar (LK);</li>\n      <li>Befarin (TH);</li>\n      <li>Circuvit (AR);</li>\n      <li>Cofarin (TW);</li>\n      <li>Coumadan (AR);</li>\n      <li>Coumadin (AE, AU, BB, BF, BH, BJ, CI, CL, CY, DE, EC, EG, ET, GH, GM, GN, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NZ, OM, PH, PK, QA, SA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Coumadine (FR, VN);</li>\n      <li>Dagonal (UY);</li>\n      <li>Farin (BD);</li>\n      <li>Lawarin (CZ);</li>\n      <li>Lennon-Warfarin (ZA);</li>\n      <li>Mafarin (TW);</li>\n      <li>Maforan (TH);</li>\n      <li>Marevan (AE, AU, BE, BR, CN, DK, EE, FI, GB, IE, LU, MT, NO, NZ, SG);</li>\n      <li>Marfarin (HN);</li>\n      <li>Marivarin (HR);</li>\n      <li>Martefarin (HR);</li>\n      <li>Morfarin (TH);</li>\n      <li>Oldin (PY);</li>\n      <li>Orfarin (JO, LV, MY, TH, TW);</li>\n      <li>Panwarfin (GR);</li>\n      <li>Rilaquin (PY);</li>\n      <li>Simarc-2 (ID);</li>\n      <li>UniWarfin (IN);</li>\n      <li>Varfareks (UA);</li>\n      <li>Varfarin (HR);</li>\n      <li>Varfine (PT);</li>\n      <li>Waran (SE);</li>\n      <li>Warf (LK);</li>\n      <li>Warfant (IE, TR);</li>\n      <li>Warfar (CO, KR);</li>\n      <li>Warfarina (PE);</li>\n      <li>Warfil 5 (DO);</li>\n      <li>Warfin (PL);</li>\n      <li>Warik (PH);</li>\n      <li>Warin (BD);</li>\n      <li>Win (BD);</li>\n      <li>Zofarin (LK);</li>\n      <li>Zydarin (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ageno W, Gallus AS, Wittkowsky A, et al, &ldquo;Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e44-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315269/pubmed\" target=\"_blank\" id=\"22315269\">22315269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anand SS, Yusuf S, Pogue J, et al, &ldquo;Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non-Q-Wave Myocardial Infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study Results,&rdquo; <i>Circulation</i>, 1998, 98(11):1064-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/9736592/pubmed\" target=\"_blank\" id=\"9736592\">9736592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arepally GM and Ortel TL, &ldquo;Heparin-Induced Thrombocytopenia,&rdquo; <i>N Engl J Med</i>, 2006, 355 (8):809-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16928996/pubmed\" target=\"_blank\" id=\"16928996\">16928996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armstrong MJ, Gronseth G, Anderson DC, et al. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2013;80(22):2065-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23713086/pubmed\" target=\"_blank\" id=\"23713086\">23713086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baillargeon J, Holmes HM, Lin YL, et al, &quot;Concurrent Use of Warfarin and Antibiotics and the Risk of Bleeding in Older Adults,&quot; <i>Am J Med</i>, 2012, 125(2):183-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22269622/pubmed\" target=\"_blank\" id=\"22269622\">22269622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e691-736.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo; <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/21640290/pubmed\" target=\"_blank\" id=\"21640290\">21640290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>J Am Coll Cardiol</i>, 2008, 52(18):1502-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. <i>Nutr Rev</i>.1999;57(9):288-296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/10568341/pubmed\" target=\"_blank\" id=\"10568341\">10568341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carabello PJ, Heit JA, Atkinson EJ, et al, &ldquo;Long-Term Use of Oral Anticoagulants and the Risk of Fracture,&rdquo; <i>Arch Intern Med</i>, 1999, 159(15):1750-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/10448778/pubmed\" target=\"_blank\" id=\"10448778\">10448778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chimowitz MI, Lynn MJ, Howlett-Smith H, et al, &quot;Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis,&quot; <i>N Engl J Med</i>, 2005, 352(13):1305-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/15800226/pubmed\" target=\"_blank\" id=\"15800226\">15800226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coumadin (warfarin) [prescribing information]. Princeton, NJ: Bristol-Meyers Squibb; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation. <i>Neurology</i>. 2014;82:716-724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24566225/pubmed\" target=\"_blank\" id=\"24566225\">24566225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE and White RH, &ldquo;Pharmacotherapy of Heparin-Induced Thrombocytopenia,&rdquo; <i>Expert Opin Pharmacother</i>, 2003, 4(6):919-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/12783589/pubmed\" target=\"_blank\" id=\"12783589\">12783589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, King JF, Regalia RC, et al, &ldquo;Reversal of Elevated International Normalized Ratios and Bleeding With Low-Dose Recombinant Activated Factor VII in Patients Receiving Warfarin,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(8):1091-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16863486/pubmed\" target=\"_blank\" id=\"16863486\">16863486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Effect of Long-Term Oral Anticoagulant Treatment on Mortality and Cardiovascular Morbidity After Myocardial Infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group,&rdquo; <i>Lancet</i>, 1994, 343(8896):499-503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/7906757/pubmed\" target=\"_blank\" id=\"7906757\">7906757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gage BF, Birman-Deych E, Radford MJ, et al, &ldquo;Risk of Osteoporotic Fracture in Elderly Patients Taking Warfarin. Results From the National Registry of Atrial Fibrillation 2,&rdquo; <i>Arch Intern Med</i>, 2006, 166(2):241-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16432096/pubmed\" target=\"_blank\" id=\"16432096\">16432096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grand&rsquo;Maison A, Charest AF, and Geerts WH, &ldquo;Anticoagulant Use in Patients With Chronic Renal Impairment,&rdquo; <i>Am J Cardiovasc Drugs</i>, 2005, 5(5):291-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16156685/pubmed\" target=\"_blank\" id=\"16156685\">16156685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harrell CC, Kline SS. Vitamin K-supplemented snacks containing olestra: implication for patients taking warfarin. <i>JAMA</i>. 1999; 282(12):1133-1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/10501114/pubmed\" target=\"_blank\" id=\"10501114\">10501114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthcare Environmental Resource Center (HERC), &quot;Pharmaceutical Wastes in Healthcare Facilities.&quot; Available at http://www.hercenter.org/hazmat/pharma.cfm#listed. Last accessed April 8, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo; <i>Circulation</i>, 2011, 123(16):1788-830.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/21422387/pubmed\" target=\"_blank\" id=\"21422387\">21422387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jamal SA, Browner WS, Bauer DC, et al, &ldquo;Warfarin Use and Risk for Osteoporosis in Elderly Women. Study of Osteoporotic Fractures Research Group,&rdquo; <i>Ann Intern Med</i>, 1998, 128(10):829-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/9599195/pubmed\" target=\"_blank\" id=\"9599195\">9599195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000041</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeske AH, Suchko GD, ADA Council on Scientific Affairs and Division of Science, et al, &ldquo;Lack of a Scientific Basis for Routine Discontinuation of Oral Anticoagulation Therapy Before Dental Treatment,&rdquo; <i>J Am Dent Assoc</i>, 2003, 134(11):1492-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/14664269 /pubmed\" target=\"_blank\" id=\"14664269 \">14664269 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karsli ED, Erdogan &Ouml;, Esen E, et al, &quot;Comparison of the Effects of Warfarin and Heparin on Bleeding Caused by Dental Extraction: A Clinical Study,&quot; <i>J Oral Maxillofac Surg</i>, 2011, 69(10):2500-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/21764203/pubmed\" target=\"_blank\" id=\"21764203\">21764203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovacs MJ, Rodger M, Anderson DR, et al, &ldquo;Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together With Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. A Randomized, Double-Blind, Controlled Trial,&rdquo; <i>Ann Intern Med</i>, 2003, 138(9):714-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/12729425/pubmed\" target=\"_blank\" id=\"12729425\">12729425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuykendall JR , Houle MD, Rhodes RS. Possible warfarin failure due to interaction with smokeless tobacco. <i>Ann Pharmacother</i>. 2004;38(4):595-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/14766993/pubmed\" target=\"_blank\" id=\"14766993\">14766993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Little JW, Miller CS, Henry RG, et al, &ldquo;Antithrombotic Agents: Implications in Dentistry,&rdquo; <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>, 2002, 93(5):544-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/12075203 /pubmed\" target=\"_blank\" id=\"12075203 \">12075203 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo; <i>Circulation</i>, 2009, 119(16):2250-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/19332472/pubmed\" target=\"_blank\" id=\"19332472\">19332472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMahan DA, Smith DM, Carey MA, et al, &ldquo;Risk of Major Hemorrhage for Outpatients Treated With Warfarin,&rdquo; <i>J Gen Intern Med</i>, 1998, 13(5):311-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/9613886/pubmed\" target=\"_blank\" id=\"9613886\">9613886</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meschia JF, Bushnell C, Boden-Albala B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014;45(12):3754-3832.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/25355838/pubmed\" target=\"_blank\" id=\"25355838\">25355838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan A, Goldenberg NA, et al, &quot;Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),&quot; <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. <i>Am J Kidney Dis</i>. 2015;66(1):133-146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/25960299/pubmed\" target=\"_blank\" id=\"25960299\">25960299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. <i>J Thromb Thrombolysis</i>. 2011;31:326-343.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/21359645/pubmed\" target=\"_blank\" id=\"21359645\">21359645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu E, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. <i>Expert Opin Drug Saf</i>. 2006;5(3):433-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16610971/pubmed\" target=\"_blank\" id=\"16610971\">16610971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patriquin C and Crowther M, &ldquo;Treatment of Warfarin-associated Coagulopathy With Vitamin K,&rdquo; <i>Expert Rev Hematol</i>, 2011, 4(6):657-67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Puskas J, Gerdisch M, Nichols D, et al; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial. <i>J Thorac Cardiovasc Surg</i>. 2014;147(4):1202-1211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24512654 /pubmed\" target=\"_blank\" id=\"24512654 \">24512654 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Randomised Double-Blind Trial of Fixed Low-Dose Warfarin With Aspirin After Myocardial Infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators,&rdquo; <i>Lancet</i>, 1997, 350(9075):389-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/9259652/pubmed\" target=\"_blank\" id=\"9259652\">9259652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacco RL, Adams R, Albers G, et al, &ldquo;Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology Affirms the Value of this Guideline,&rdquo; <i>Stroke</i>, 2006, 37(2):577-617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16432246/pubmed\" target=\"_blank\" id=\"16432246\">16432246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scully C and Wolff A, &ldquo;Oral Surgery in Patients on Anticoagulant Therapy,&rdquo; <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>, 2002, 94(1):57-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/12193895 /pubmed\" target=\"_blank\" id=\"12193895 \">12193895 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer DE, Albers GW, Dalen JE, et al, &ldquo;Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&rdquo; Chest, 2008, 133(6 Suppl):546-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/18574273/pubmed\" target=\"_blank\" id=\"18574273\">18574273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith P, Arnesen H, and Holme I, &ldquo;The Effect of Warfarin on Mortality and Reinfarction After Myocardial Infarction,&rdquo; <i>N Engl J Med</i>, 1990, 323(3):147-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/2194126/pubmed\" target=\"_blank\" id=\"2194126\">2194126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smythe MA, Warkentin TE, Stephens JL, et al, &ldquo;Venous Limb Gangrene During Overlapping Therapy With Warfarin and a Direct Thrombin Inhibitor for Immune Heparin-Induced Thrombocytopenia,&rdquo; <i>Am J Hematol</i>, 2002, 71(1):50-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/12221676/pubmed\" target=\"_blank\" id=\"12221676\">12221676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stein PD, Alpert JS, Bussey HI, et al, &ldquo;Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves,&rdquo; Chest, 2001, 119(1 Suppl):220-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/11157651/pubmed\" target=\"_blank\" id=\"11157651\">11157651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suvarna R, Pirmohamed M, and Henderson L, &ldquo;Possible Interaction Between Warfarin and Cranberry Juice,&rdquo; <i>BMJ</i>, 2003, 327(7429):1454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/14684645/pubmed\" target=\"_blank\" id=\"14684645\">14684645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    United States Department of Agriculture (USDA), National Agricultural Library (NAL) <i>Dietary Reference Intake</i>. Available at <a href=\"http://fnic.nal.usda.gov/dietary-guidance/dietary-reference-intakes/dri-tables\" target=\"_blank\">http://fnic.nal.usda.gov/dietary-guidance/dietary-reference-intakes/dri-tables</a>. Accessed January 8, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitlock RC, Sun JC, Fremes, SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 suppl):e576S-e600S. doi: 10.1378/chest.11-2305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315272/pubmed\" target=\"_blank\" id=\"22315272\">22315272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandvik PO, Lincoff AM, Gore JM, et al.. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 suppl):e637S-e668S. doi: 10.1378/chest.11-2306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315274/pubmed\" target=\"_blank\" id=\"22315274\">22315274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yung D, Kapral MK, Asllani E, et al, Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the best practice for reinitiating anticoagulation therapy after intracranial bleeding (BRAIN) study. <i>Can J Cardiol</i>. 2012;28:33-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22153256/pubmed\" target=\"_blank\" id=\"22153256\">22153256</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10050 Version 274.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708848\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F234876\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F234877\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F234916\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F234880\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F234898\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F234881\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F3401678\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F234882\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F234849\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F234833\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28843154\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874933\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F234853\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104604\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F234852\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744940\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F234925\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234840\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F234856\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F234837\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F234911\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234842\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F234872\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F234859\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F234860\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F234861\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F234847\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F234850\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234836\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F234855\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F234858\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234862\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10050|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=warfarin-patient-drug-information\" class=\"drug drug_patient\">Warfarin: Patient drug information</a></li><li><a href=\"topic.htm?path=warfarin-pediatric-drug-information\" class=\"drug drug_pediatric\">Warfarin: Pediatric drug information</a></li></ul></div></div>","javascript":null}